GENE ONLINE|News &
Opinion
Blog

2020-08-17| R&DSpecialTechnology

Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)

by GeneOnline
Share To
Advances in genetics, pharmacology, and an improved understanding of molecular mechanisms have enabled the treatment of debilitating neurodegenerative diseases with high precision. Among the various cutting-edge treatment approaches, antisense oligonucleotides (ASOs) represent a promising approach by enabling reductions or modifications in RNA and protein expression. Approved ASO therapies for Neurodegenerative and Neuromuscular Diseases

GO Prime with only $1.49 now

LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top